Keyword: Department of Justice
AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
During Insys founder John Kapoor's criminal trial, prosecutors played a video urging sales reps to break the rules when promoting its opioid Subsys.
More than a year after CNN's exposé about Avanir's Neudexta marketing, the company is nearing a settlement with U.S. officials.
Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
Two Democratic senators are looking into whether Rudy Giuliani secured leniency for Purdue Pharma through conflicts of interest.
Trump's request comes as the DOJ and DEA propose to cut production quotas for the six most frequently misused opioids by 10% next year.
The $150 million is in line with Insys' previous estimate, and the final deal could include contingency-based payments of up to $75 million.
Pfizer was also cited in a lawsuit alleging U.S. companies funded terrorism by bribing Iraqi officials.
The Justice Department is eyeing claims that AstraZeneca bribed Iraqi health officials to win contracts even after Shiite terrorists took over.